Nevirapin Axiromed (Nevirapine)

Nevirapine belongs to the non‑nucleoside reverse transcriptase inhibitor (NNRTI) class. It binds to a specific non‑nucleoside site on the HIV‑1 reverse transcriptase enzyme, causing a conformational change that blocks the enzyme’s ability to convert viral RNA into DNA, thereby halting viral replication.

The dosing regimen for Nevirapin Axiromed is determined by the prescribing clinician based on the patient’s clinical status, weight, and treatment guidelines. Physicians typically start with a loading dose followed by a maintenance dose, but the exact schedule should be individualized and confirmed by the prescriber.

Safety data for nevirapine in pregnancy and lactation are limited. While it may be used when the benefits outweigh potential risks, clinicians should monitor liver function closely and discuss possible fetal or infant exposure with the patient. Breastfeeding decisions should follow local guidelines and professional advice.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nevirapin Axiromed (nevirapine) is one of several NNRTIs used for HIV‑1 therapy. Compared with agents such as efavirenz or rilpivirine, nevirapine has a longer history of use and a distinct side‑effect profile, including a higher risk of rash and hepatotoxicity. Choice of NNRTI depends on patient tolerance, resistance patterns, drug‑drug interactions and treatment guidelines.

Nevirapin Axiromed should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Nevirapin Axiromed is taken orally, usually with food or a light snack to improve absorption and reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious adverse events associated with nevirapine include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and hepatotoxicity that can progress to liver failure. Patients should be educated to report any rash, blistering, jaundice, dark urine, or unexplained fatigue promptly.

Nevirapin Axiromed should be avoided in individuals with a known hypersensitivity to nevirapine or any component of the formulation. It is also contraindicated in patients with pre‑existing severe liver disease or a history of severe cutaneous adverse reactions to NNRTIs. Clinicians must assess each patient’s medical history before initiating therapy.